Literature DB >> 22192113

High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection.

Thomas Clements1, Jamie C Messer, John D Terrell, Michael P Herman, Casey K Ng, Douglas S Scherr, Benjamin Scoll, Stephen A Boorjian, Robert G Uzzo, Mark Wille, Scott E Eggener, Steven M Lucas, Yair Lotan, Shahrokh F Shariat, Jay D Raman.   

Abstract

BACKGROUND AND
PURPOSE: Accurate assessment of upper-tract urothelial carcinoma (UTUC) pathology may guide use of endoscopic vs extirpative therapy. We present a multi-institutional cohort of patients with UTUC who underwent surgical resection to characterize the association of ureteroscopic (URS) biopsy features with final pathology results. PATIENTS AND METHODS: URS biopsy data were available in 238 patients who underwent surgical resection of UTUC. Biopsies were performed using a brush biopsy kit, mechanical biopsy device, or basket. Stage was classified as a positive brush, nonmuscle-invasive (<pT(2)), or muscle invasive (MI; ≥pT(2)). Grade was classified as low or high.
RESULTS: On URS biopsy, 88/238 (37%) patients had a positive brush, 140 (59%) had a diagnosis of non-MI, and 10 (4%) had MI disease. Biopsy results showed low-grade cancer in 140 (59%) and high-grade cancer in 98 (41%). Pathologic evaluation at surgical resection demonstrated non-MI tumors in 140 (59%) patients, MI in 98 (41%), and high-grade disease in 150 (63%). On univariate analysis, high URS biopsy grade was associated with high-grade (positive predictive value [PPV] 92%, P<0.0001) and MI (PPV 60%, P<0.0001) UTUC at surgery. URS biopsy stage, however, was associated with surgical pathology grade (P=0.005), but not MI (P=0.16) disease. On multivariate analysis, high URS grade, but not biopsy stage, was associated with high final pathology grade (hazard ratio [HR] 16.6, 95% confidence interval [CI] 7.0-39.5, P<0.0001) and MI UTUC (HR 3.6, 95% CI 2.1-6.8, P<0.0001).
CONCLUSION: High URS biopsy grade, but not stage, is associated with adverse tumor pathology. This information may play a valuable role for risk stratification and in the appropriate selection of endoscopic management vs surgical extirpation for UTUC.

Entities:  

Mesh:

Year:  2012        PMID: 22192113     DOI: 10.1089/end.2011.0426

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  22 in total

1.  [Elective organ and function preservation in ureter and renal pelvis tumors].

Authors:  S Rausch; G Gakis; J Bedke; A Stenzl
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

2.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

3.  Conservative treatment of upper urinary tract carcinoma: Long-term results.

Authors:  Andrea Orosa Andrada; Inés Laso García; Fernando Arias Fúnez; Francisco Donis Canet; Gemma Duque Ruiz; Victoria Gómez Dos Santos; Francisco Javier Burgos Revilla
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

4.  Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data.

Authors:  Goutham Vemana; Eric H Kim; Sam B Bhayani; Joel M Vetter; Seth A Strope
Journal:  Urology       Date:  2016-05-24       Impact factor: 2.649

5.  The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database.

Authors:  Laurent Nison; Morgan Rouprêt; Grégory Bozzini; Adil Ouzzane; François Audenet; Géraldine Pignot; Alain Ruffion; Jean-Nicolas Cornu; Sophie Hurel; Antoine Valeri; Mathieu Roumiguie; Thomas Polguer; Nicolas Hoarau; Olivier Mérigot de Treigny; Evanguelos Xylinas; Alexandre Matte; Stéphane Droupy; Pierre Olivier Fais; Aurélien Descazeaud; Pierre Colin
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

Review 6.  Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).

Authors:  Francesco Soria; Shahrokh F Shariat; Seth P Lerner; Hans-Martin Fritsche; Michael Rink; Wassim Kassouf; Philippe E Spiess; Yair Lotan; Dingwei Ye; Mario I Fernández; Eiji Kikuchi; Daher C Chade; Marko Babjuk; Arthur P Grollman; George N Thalmann
Journal:  World J Urol       Date:  2016-09-07       Impact factor: 4.226

7.  Does lymph node dissection during nephroureterectomy affect oncological outcomes in upper tract urothelial carcinoma patients without suspicious lymph node metastasis on preoperative imaging studies?

Authors:  Sangjun Yoo; Dalsan You; In Gab Jeong; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  World J Urol       Date:  2016-08-08       Impact factor: 4.226

8.  Multi-institutional Evaluation of Upper Urinary Tract Biopsy Using Backloaded Cup Biopsy Forceps, a Nitinol Basket, and Standard Cup Biopsy Forceps.

Authors:  Daniel J Lama; Shoaib Safiullah; Roshan M Patel; Thomas K Lee; Jyoti P Balani; Lishi Zhang; Zhamshid Okhunov; Vitaly Margulis; Stephen J Savage; Edward Uchio; Jaime Landman
Journal:  Urology       Date:  2018-04-06       Impact factor: 2.649

Review 9.  Survival differences of patients with ureteral versus pelvicalyceal tumours: a systematic review and meta-analysis.

Authors:  Krystian Kaczmarek; Artur Lemiński; Adam Gołąb; Marcin Słojewski
Journal:  Arch Med Sci       Date:  2019-11-21       Impact factor: 3.318

Review 10.  Nephron-sparing management of upper tract urothelial carcinoma.

Authors:  Jason M Farrow; Sean Q Kern; Gustavo M Gryzinski; Chandru P Sundaram
Journal:  Investig Clin Urol       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.